Please Wait
Applying Filters...
menu
    • menu
    PharmaCompass Sponsored Ads

    Virtual Booth

    Contact Supplier

    SPI Pharma has been solving formulation challenges using superior functional materials.

    Virtual Booth

    Contact Supplier

    Interquim comes from an international group of 50 companies active in the pharma, hospital, diagnostics, fine chemicals & feed sectors.

    Virtual Booth

    Contact Supplier

    Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

    Virtual Booth

    Contact Supplier

    FAMAR CDMO- From early development to commercial manufacturing.

    Virtual Booth

    Contact Supplier

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Menu

    Paliperidone Palmitate

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 43,103Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    FDA Approves Luye Pharma's ERZOFRI For Schizophrenia Treatment
    FDA Approves Luye Pharma's ERZOFRI For Schizophrenia Treatment

    28 Jul 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/luye-pharma-announces-us-fda-approval-of-erzofri-paliperidone-palmitate-extended-release-injectable-suspension-for-treating-schizophrenia-and-schizoaffective-disorder-302208155.html

    PR NEWSWIRE
    28 Jul 2024
    Share Share
    New Data Provide Schizophrenia Insights On Switching To UZEDY
    New Data Provide Schizophrenia Insights On Switching To UZEDY

    01 Jun 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240601180710/en

    BUSINESSWIRE
    01 Jun 2024
    Share Share
    Teva, Viatris win new chance to challenge J&J schizophrenia drug patent
    Teva, Viatris win new chance to challenge J&J schizophrenia drug patent

    02 Apr 2024

    // REUTERS

    https://www.reuters.com/business/healthcare-pharmaceuticals/teva-viatris-win-new-chance-challenge-jj-schizophrenia-drug-patent-2024-04-01/

    REUTERS
    02 Apr 2024
    Share Share
    Pharmascience's Generic Paliperidone Palmitate Receives Approval in the U.S.
    Pharmascience's Generic Paliperidone Palmitate Receives Approval in the U.S.

    05 Feb 2024

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210397

    FDA
    05 Feb 2024
    Share Share
    Tolmar's Generic Paliperidone Palmitate Receives Approval in the U.S.
    Tolmar's Generic Paliperidone Palmitate Receives Approval in the U.S.

    30 Jun 2023

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211995

    FDA
    30 Jun 2023
    Share Share
    Byannli authorised in Britain for schizophrenia treatment
    Byannli authorised in Britain for schizophrenia treatment

    01 Feb 2022

    // PHARMATIMES

    https://www.pharmatimes.com/news/byannli_authorised_in_britain_for_schizophrenia_treatment_1387028

    PHARMATIMES
    01 Feb 2022
    Share Share